Leukemia & Lymphoma

Papers
(The H4-Index of Leukemia & Lymphoma is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study84
Impact of SF3B1 mutation in myelofibrosis46
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma41
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia33
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant31
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review25
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia25
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis24
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma24
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents23
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination22
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia22
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study21
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma21
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia20
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis20
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management19
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes19
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma19
0.062047004699707